Compare WY & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WY | WAT |
|---|---|---|
| Founded | 1900 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 29.3B |
| IPO Year | 1994 | 1996 |
| Metric | WY | WAT |
|---|---|---|
| Price | $23.73 | $305.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $29.00 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 5.3M | 999.3K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | 0.45 | ★ 10.76 |
| Revenue | ★ $6,905,000,000.00 | $3,165,286,000.00 |
| Revenue This Year | $6.14 | $104.66 |
| Revenue Next Year | $8.91 | $10.53 |
| P/E Ratio | $52.39 | ★ $28.06 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $21.16 | $275.05 |
| 52 Week High | $30.06 | $414.15 |
| Indicator | WY | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 41.96 |
| Support Level | $23.23 | $281.62 |
| Resistance Level | $24.03 | $308.14 |
| Average True Range (ATR) | 0.55 | 8.07 |
| MACD | 0.01 | 2.99 |
| Stochastic Oscillator | 52.76 | 64.39 |
Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.